随着FDA在得克萨斯州获胜,Hims & Hers Health's shown's shown's stock down as FDA win in Texas 可能结束关键重量损失药物成分的短缺。 Hims & Hers Health's stock falls as FDA win in Texas may end shortage of key weight loss drug ingredient.

在得克萨斯州的一项法院裁决有利于食品药品管理局之后,Hims & hers Health的库存下降了9.2%,这有可能结束Tirzepatide的短缺,Tirzepatide是减肥药物中的一个关键成分。 Hims & Hers Health's stock dropped by 9.2% after a court ruling in Texas favored the FDA, potentially ending a shortage of tirzepatide, a key ingredient in weight loss drugs. 这可能伤害Hims & Hers的生意和股票价值,因为他们依赖添加这种成分。 This could hurt Hims & Hers' business and stock value as they rely on compounding this ingredient. 该公司的仿制GLP-1减重药品激增,以前增加了库存量,但现在由于法律裁决而面临挑战。 The surge in copycat GLP-1 weight-loss drugs by the company had previously boosted its stock but now faces challenges due to legal rulings.